ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1477

Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials

Vibeke Strand1, Rita Ganguly2, Nan Li3, Prasheen Agarwal3, Shihong Sheng3, Kaiyin Fei3, Kelly McQuarrie3 and Sharon Popik3, 1Division of Immunology/Rheumatology, Stanford University, Stanford, CA, 2GlaxoSmithKline, Collegeville, PA, 3Janssen Research & Development, LLC, Spring House, PA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biologics, Clinical Response, patient-reported outcome measures, rheumatoid arthritis (RA) and rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Sirukumab, a selective, high-affinity, human anti–IL-6 monoclonal antibody, is in development for rheumatoid arthritis (RA) and other diseases.  Effects of sirukumab on RA symptoms and disease activity and health-related physical and emotional well-being were evaluated in 2 phase 3 randomized controlled trials (RCTs) in RA pts with inadequate responses to conventional DMARDs (SIRROUND-D) or TNF inhibitors (TNFi; SIRROUND-T).  Across both RCTs, significant improvements were observed in all 8 SF-36 domains with both evaluated sirukumab doses (50 mg q4w and 100 mg q2w) versus placebo (PBO; P<0.001).

Methods: In both RCTs, eligible pts were randomized (1:1:1) to treatment with SC sirukumab 50 mg q4w, sirukumab 100 mg q2w, or PBO.  Durations of PBO treatment were 52 and 24 wks, respectively, in SIRROUND-D and SIRROUND-T.  Efficacy of sirukumab was evaluated using traditional RA endpoints.  This analysis included SDAI and CDAI scores and the following patient-reported outcomes (PROs): pt global assessment of disease activity, pain (0-10 VAS), HAQ-DI, FACIT-Fatigue, and SF-36 health survey.  In this post-hoc analysis, correlations between changes from baseline (BL; at Wks 16 [primary endpoint] or 24) in disease activity, symptoms, and SF-36 domain scores were evaluated.  Last observation carried forward was used for imputing missing data.

 

Results: For changes from BL to Wk 16 in SIRROUND-T, correlation coefficients (r) were low to moderate between all 8 SF-36 domains and SDAI (r ranging from −0.535 to −0.208) and CDAI (−0.526 to −0.209; Table).  Low to moderate correlations were also observed between changes from BL to Wk 16 in 7 of 8 SF-36 domains and pt global assessment scores (r ranging from −0.461 to −0.267) in SIRROUND-T, and a high correlation was observed for the remaining domain, bodily pain (−0.665 to −0.619).  Moderate correlations were observed between changes from BL to Wk 16 in the SF-36 bodily pain, physical function, social function, and role-physical domains and changes in HAQ-DI (r ranging from −0.560 to −0.310).  Moderate to high correlations were observed for changes from BL to Wk 16 in 7 of 8 SF-36 domains and FACIT-Fatigue scores (r ranging from 0.392 to 0.627; Table).  As anticipated, changes from BL to Wk 16 in VAS pain and SF-36 bodily pain domain were highly correlated (r ranging from −0.672 to −0.661; Table).  Correlations were generally higher with sirukumab than placebo.  Similar correlations were observed in changes from BL to Wk 16 in SIRROUND-D.  These correlations were maintained at Week 24 in both RCTs.

 

Conclusion: Results of these analyses highlight the importance of PROs, including SF-36 and FACIT-Fatigue, as independent measures of treatment success.  Although some SF-36 domains are moderately correlated with clinical responses, these findings indicate that SF-36 captures aspects of patient well-being not covered by standard measures of RA symptoms and disease activity.


Disclosure: V. Strand, AbbVie, Amgen, AstraZeneca, Biogen Idec, Boehringer Ingelheim, Celltrion, Crescendo, Genentech/Roche, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sanofi, and UCB, 5; R. Ganguly, GlaxoSmithKline, 1,GlaxoSmithKline, 3; N. Li, Johnson & Johnson, 3,Johnson & Johnson, 1; P. Agarwal, Johnson & Johnson, 1,Johnson & Johnson, 3; S. Sheng, Johnson & Johnson, 1,Johnson & Johnson, 3; K. Fei, Johnson & Johnson, 1,Johnson & Johnson, 3; K. McQuarrie, Johnson & Johnson, 1,Johnson & Johnson, 3; S. Popik, Johnson & Johnson, 1,Johnson & Johnson, 3.

To cite this abstract in AMA style:

Strand V, Ganguly R, Li N, Agarwal P, Sheng S, Fei K, McQuarrie K, Popik S. Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/patient-reported-outcomes-as-independent-measures-of-treatment-success-with-sirukumab-an-anti-il6-cytokine-monoclonal-antibody-in-patients-with-active-rheumatoid-arthritis-post-hoc-analysis-of-2-pl/. Accessed May 16, 2022.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-outcomes-as-independent-measures-of-treatment-success-with-sirukumab-an-anti-il6-cytokine-monoclonal-antibody-in-patients-with-active-rheumatoid-arthritis-post-hoc-analysis-of-2-pl/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.